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Dr Joseph Shrager (Stanford, Calif). I have no conflicts. I con-
gratulate Dr Darling and coauthors for a carefully conducted study
on a subject that has daily practical relevance. We heard from this
data set in 2005 that lymph node dissection causes no increasedmor-
bidity or mortality versus sampling, and today’s presentation gives
us the long-awaited survival data. The results, as you heard, show
that there is no difference in either overall or disease-free survival
whether one does a complete dissection versus an aggressive sam-
pling in the early stages thatwere studied. But despite these findings,
you recommend that a complete dissection is the procedure of
choice, because, and I quote loosely, ‘‘it improves the accuracy of
staging and thus the selection of patients for adjuvant therapy.’’
I would agree with your conclusion that complete dissection
remains preferable, but for completely different reasons than those
you describe. Only 4% of additional patients were found to have
positive nodes at dissection that were missed at sampling, and
presumably most of these patients then received adjuvant chemo-
therapy, yet there was still no survival advantage to the dissection.ery c March 2011
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SSo I don’t understand why ‘‘better staging’’ is a good reason to do
a complete dissection, and I don’t think that surgeons will buy that
reasoning, honestly.
My reasoning for continuing to do complete dissections would
be that the sampling stipulated in the protocol is not at all a real-
world sampling, and few surgeons would actually be doing that
type of extensive sampling. With a less extensive, more real-world
sampling, you would have found more than 4% additional nodes at
complete dissection, and so you would possibly also have found
a significantly increased survival. So I think it is dangerous for ev-
eryone to leave the meeting thinking that sampling is okay. As you
emphasized, sampling is only okay if you have done this particular
systematic, extensive sampling with frozen sections as stipulated
in the study, and that is a sampling that pretty much approached
being a total lymphadenectomy. If your sampling is going to be
that extensive, it is probably more efficient to just do a lymphade-
nectomy from the start. I have 3 specific questions.
First, the article describes a power analysis that arrived at a tar-
get accrual of 1037, which you nearly achieved, but I would guess
that that power analysis was based on a likelihood of identifying
more than only 4% additional nodes at the time of the lymphade-
nectomy. So are you concerned that you have sort of a type II error,
that is, a false-negative result?
Dr Darling. First, my comment on your comment, and that is
we know from the previous pattern of care study that you are cor-
rect. In fact, less than half the patients who have surgery for
NSCLC in North America actually have any kind of lymph node
sampling performed at mediastinoscopy or before resection. So
these results don’t reflect the real world but may inform real-world
practice, and I would echo your comments that the patients were
rigorously staged and our results don’t apply to patients who don’t
have that kind of sampling. This is supported by the literature. The
survival benefit for lymph node dissection shown in studies was in
a group of patients who did not have any kind of preresection sam-
pling or staging, and therefore their finding of so-called occult N2
disease was much higher.
In terms of your question about the power, the overall sample
size was based on the primary aim of comparing overall survival
betweenMLND andMLNS. Because of the limited number of sub-
jects enrolled with higher stage disease (ie, pN1 and pN2/pIIIA),
the power for the study was amended. This amendment was ap-
proved by the National Cancer Institute. The amended power cal-
culation presented in the article assumes the following proportions
for stage groups pT1N0 (41%), pT2N0 (41%), pN1 (13%), and
pN2/IIIA (4%) in theMLNS arm. The power calculation was based
on a 1-sided, alpha ¼ 0.05 log rank test for 90% power, which re-
sulted in needing to enroll 1037 subjects. We enrolled 1111 sub-
jects, of whom 1023 were deemed eligible. As described in the
article, both intent-to-treat analyses on all randomized subjects
and analyses limited to the eligible subjects were performed. Var-
ious power scenarios were considered for the secondary aim of
identifying occult metastases. For example, if 5% pN2 nodes
were discovered in theMLNS versus 10% in the MLND dissection
arm, there would be more than 90% power. On the basis of the ob-
served differences, we think the study was adequately powered.
Dr Shrager. You showed us the results in the T1 and T2
subgroups. I wonder about the N0 and N1 subgroups. Because
there is certainly going to be more occult N2 disease in thoseThe Journal of Thoracic and Cawith clinical N1 than in those with clinical N0, most of us would
be pretty concerned about leaving out a complete lymphadenec-
tomy in somebody who has clinical N1.
DrDarling. The study protocol mandated that only patients with
nonhilar N1 were eligible and the hilar nodes had to be sampled,
proven to be negative by frozen-section for the patient to be eligible.
The actual number of patients withN1 is relatively small. So anyN1
nodes that were present were actually within the lobectomy speci-
men. This is similar to the real world: The surgeon would not
know the status of the intralobar nodes, only the hilar nodes. So,
in the study population, the highest resected nodes were negative.
Dr Shrager. I wonder if you think this study has any relevance
to the role of VATS lobectomy? As you know, many continue to
find that doing a true complete mediastinal lymphadenectomy is
difficult to do thoracoscopically. However, if complete dissection
is of little benefit over a good sampling, is the last barrier to a wider
acceptance of VATS lobectomy for earlier stage disease gone?
Dr Darling. If we are going to do lung cancer surgery by VATS,
we need to do the same operation that we do when we do it open,
and that includes a lymph node dissection or a rigorous sampling,
and I don’t think it is appropriate for us to just simply go in and
take out the lobe and not do a proper sampling of the lymph nodes.
Only 7% of the patients in this study were resected by VATS, and
that was primarily done by one surgeon. Dr Allen and I reviewed
all the path and operative notes from all the patients in the trial, and
particularly we reviewed those VATS cases because of our bias that
maybe they wouldn’t have had an adequate dissection or sampling.
In that particular surgeon’s hands, an adequate dissection was done
and the lymph node counts were comparable to those taken with
open surgery. So I think it is possible to do a good lymph node dis-
section or sampling with VATS technique, and it behooves us as
thoracic surgeons who treat lung cancer to do the same job with
VATS as we do with open.
Dr Thomas D’Amico (Durham, NC). Could you just clarify
how you did the audit to make sure that a sampling or a dissection
was done?
Dr Darling. As I mentioned, we reviewed all the operative
notes and looked at the numbers of lymph nodes that were actually
removed, and we actually disqualified some patients because they
had excessive sampling or had not had an adequate dissection.
Dr Allen and I both reviewed those results. We eliminated some
of the patients because they didn’t follow the protocol.
Dr D’Amico. What percentage of patients were upstaged so
that treatment was changed? Were any of the 4% of N2 also N1
so that they would have received chemotherapy anyway?
Dr Darling. Of the 21 patients, 11 had N1 disease. This trial
was completed in 2004. So at that time, adjuvant chemotherapy
was not recommended for N1 disease. In reference to Dr Shrager’s
previous comment, these patients did not necessarily receive adju-
vant therapy at that time, but nowadays they would, and this may
have improved survival.
Dr Marcin Zielinski (Zakopane, Poland). I have 2 questions.
First, what was the mean number of nodes removed during lym-
phadenectomy in the lymphadenectomy group?
Dr Darling. The median number of N2 nodes taken was 11 on
the right and 12 on the left, but if all nodal stations are included, the
median number of nodes taken was 18. Ninety-nine percent of our
patients had 6 or more nodes taken from 3 mediastinal lymph noderdiovascular Surgery c Volume 141, Number 3 669
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Commentary Murthystations and 90% had 10 or more nodes removed from 3 mediasti-
nal lymph node stations.
Dr Zielinski. My second question is, do you know how many
patients were positive on the initial sampling with frozen-section?
Dr Darling. We don’t have that data because they were not
eligible to be randomized.
Dr Paul De Leyn (Leuven, Belgium). That was a nice presenta-
tion. When you read the article in 2005, which describes morbidity
and mortality, you indeed think that the sampling is already exten-
sive, and this is important. Can you describe from a technical point
of viewwhen you sample, let’s say, station 7, is this just picking out
a few nodes or is this removing this whole station? What is the dif-
ference between sampling and dissection in your study?COMMEN
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670 The Journal of Thoracic and Cardiovascular SurgDrDarling.The sampling protocol specified that you were sim-
ply directed to sample one node from each station. If there were
any suspicious-looking nodes, obviously they were also required
to be sampled as opposed to doing a formal clean-out of the
area. So the protocol did specify to sample 1 node. Occasionally
the surgeons would take more than 1 node, but, as I mentioned,
if they took a whole lot of nodes (eg, 5–7 nodes from station 7),
we disqualified those as being a dissection rather than a sampling.
For the lymph node dissection, the protocol specified removing all
lymph node-bearing tissues between anatomic boundaries. For ex-
ample, for stations 2R and 4R all tissue between the superior vena
cava, trachea, right innominate artery, and the right bronchus was
removed, not just the visible lymph nodes.TARYLess is more. (more or less.)Sudish C. Murthy, MD, PhDIn this month’s issue, Dr Darling and colleagues present the
results of a long-awaited multicenter, prospective, random-
ized trial comparing efficacy of mediastinal lymph node
sampling (MLNS) and mediastinal lymph node dissection
(MLND) for localized non–small cell lung cancer (NSCLC).
This study was one of the many ‘‘brain-children’’ of the late
Dr Robert J. Ginsberg, and its organization, attention to de-
tail, and insight speak to the lasting legacy of this pioneer. In
addition, the group of distinguished authors who carried this
trial to its conclusion has overcome enormous obstacles to
complete this ambitious enterprise, dutifully and meticu-
lously organizing data collected from over 100 surgeons at
63 member institutions while maintaining some element
of quality control throughout the process—truly a formida-
ble task whose complexity should be appreciated.
The importance of this trial cannot be underestimated in-
asmuch as the role of lymphadenectomy for NSCLC, until
now, has served as a point of confusion for most thoracicsurgical oncologists. Although widely heralded as an im-
portant adjunct for management of the disease, there has
been little evidence to support this grandiose contention
in clinical practice. In fact, a shockingly high number of
lung cancer operations are performed without a single me-
diastinal lymph node even being sampled.1 Yet, despite this,
sophisticated and detailed guidelines of howMLND should
be integrated into NSCLC management have continued to
emerge.2 At last, there is a well-done, randomized trial to
support a position on the subject.
The findings of this trial are provocative, as surprisingly,
equivalence was found between MLNS and MLND for pa-
tients with early NSCLC (N0 or nonhilar N1 cancers). This,
in part, corroborates results from a similar, albeit much
smaller and less well-controlled, trial from a decade ago.3
But the results appear to fly against the popular notion
that MLND is a superior surgical technique with important
survival benefits for patients with early-stage NSCLC.4-7
None of these lesser studies was randomized or as well
conceived, however. Importantly, after careful review of
each study, including my own, unfortunately, the authors
of the latter group of manuscripts need not ready their
retraction statements just yet, inasmuch as there may still
be room for peaceful coexistence between studies,
because slightly different questions were addressed by each.
There is a reason why such randomized studies are com-
pleted so infrequently and why this trial casts such a heroic
specter. Clearly, it is difficult to have equipoise for such
a trial if one believes strongly (either way) about MLND,ery c March 2011
